Condition

DLBCL - Diffuse Large B Cell Lymphoma clinical trials and research

• 27Clinical trials
• 12Countries

Newest DLBCL - Diffuse Large B Cell Lymphoma clinical trials

All recruiting trials (27)

• Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL

  This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.

  Recruiting at 2 sites The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT07778212

• Hypofractionated Radiotherapy plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

  This study tests a combination therapy—hypofractionated radiotherapy with GM-CSF, pomalidomide, and glofitamab—for adults newly diagnosed with primary CNS DLBCL to see if it helps control the disease.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07749365

• Modified DHAP vs Standard DHAP in relapsed/refractory DLBCL

  This phase 3 trial tests whether a split, lower-dose version of DHAP is as effective as the standard regimen for adults with relapsed or refractory DLBCL and tries to reduce toxicities.

  Recruiting Phase 3 King Edward Medical University · Lahore, Punjab Province · NCT07739654

• Orelabrutinib plus standard immunochemotherapy with or without auto-HSCT for newly diagnosed DLBCL

  This study tests whether adding orelabrutinib to standard chemotherapy, with or without autologous stem cell transplantation, helps newly diagnosed DLBCL patients.

  Recruiting Phase 2 The Affiliated Hospital of Xuzhou Medical University · Xuzhou, Jiangsu · NCT07680933

• SCTB35 with Gemcitabine and Oxaliplatin in relapsed or refractory DLBCL

  This trial tests whether SCTB35 added to gemcitabine and oxaliplatin helps people with relapsed or refractory diffuse large B-cell lymphoma stay disease-free longer compared with rituximab plus gemcitabine and oxaliplatin.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing · NCT07570823

• CT1182 CAR‑T infusion for adults with relapsed or refractory B‑cell non‑Hodgkin lymphoma

  This trial tests whether a CT1182 CAR‑T cell infusion is safe and can help adults 18–75 with relapsed or refractory B‑cell non‑Hodgkin lymphoma.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07548697

• Zamtocabtagene autoleucel (MB-CART2019.1) for relapsed or refractory diffuse large B‑cell lymphoma in Japan

  This study will test a dual-target CAR T-cell therapy (MB-CART2019.1) that targets CD19 and CD20 in people in Japan whose diffuse large B‑cell lymphoma has returned or not responded after at least two prior therapies.

  Recruiting at 2 sites Phase 2 Miltenyi Biomedicine GmbH · Tokyo and 4 other locations · NCT07288879

• Pirtobrutinib plus lisaftoclax and rituximab for relapsed or refractory DLBCL

  This trial tests whether combining pirtobrutinib, lisaftoclax, and rituximab helps people with relapsed or refractory diffuse large B‑cell lymphoma who have had at least one prior systemic therapy.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07255963

• MDX2003 for adults with relapsed B‑cell lymphomas

  This trial will test MDX2003 in adults with relapsed or refractory B‑cell lymphomas whose tumors are CD19 or CD20 positive to see if it is safe and can shrink tumors.

  Recruiting at 7 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Richmond, Victoria and 6 other locations · NCT07249905

• Safety testing of LTZ-301 in adults with relapsed or refractory B‑cell non-Hodgkin lymphoma

  This trial will test whether LTZ-301 is safe and how it behaves in adults whose B‑cell non-Hodgkin lymphoma has come back or not responded after at least two prior treatments.

  Recruiting at 6 sites Phase 1 LTZ Therapeutics, Inc. · Duarte, California and 5 other locations · NCT07121946

• Using blood inflammation markers (CRP, albumin, CAR, mGPS) to predict outcomes in diffuse large B‑cell lymphoma

  This project tests whether common blood inflammation markers (CRP, albumin, CRP-to-albumin ratio, and mGPS) can help predict how adults with newly diagnosed DLBCL will respond to standard R-CHOP chemotherapy and what side effects they may get.

  Recruiting Ain Shams University · Cairo, Cairo Governorate · NCT07057765

• Epcoritamab plus loncastuximab tesirine for relapsed or refractory large B-cell lymphoma

  This test gives epcoritamab together with loncastuximab tesirine to adults whose large B-cell lymphoma has come back or not responded, to see if it can shrink or clear the cancer.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06919939

• Combining Chidamide with R-CHOP for a specific type of lymphoma

  This study is testing if adding a new drug called chidamide to standard chemotherapy can help people with a specific type of lymphoma feel better and live longer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06891157

• Zanubrutinib with R-CHOP for DLBCL that has MYD88, CD79B, NOTCH1 changes, or is CD5+

  This study will try adding zanubrutinib to standard R-CHOP chemotherapy for adults with DLBCL who have an MYD88 L265P, CD79B, or NOTCH1 truncation mutation, or who are CD5+ by IHC.

  Recruiting Phase 2 Virginia Commonwealth University · Richmond, Virginia · NCT06846463

• Testing blood for cancer DNA in patients with B-cell lymphoma

  This study is testing if a blood test for cancer DNA can help identify patients with B-cell lymphoma who are at risk of having their cancer come back in the brain or spinal cord, even when other tests show no signs of it.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06736613

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Milaberon for treating advanced solid tumors

  This study is testing if a higher dose of mirabegron can help people with advanced solid tumors feel better while keeping an eye on any side effects.

  Recruiting Phase 2 Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT06534762

• Prognostic tool for identifying high-risk DLBCL patients

  This study is trying to create a new tool to help doctors find out which patients with diffuse large B cell lymphoma are at high risk of not responding well to their first treatment.

  Recruiting University Medical Center Goettingen · Göttingen, Lower Saxony · NCT06526065

• Evaluating glofitamab for patients with relapsed or refractory DLBCL in China

  This study is testing if glofitamab can safely help Chinese patients with relapsed or refractory diffuse large B-cell lymphoma who haven't responded to previous treatments.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06481826

• Evaluating Tafasitamab with Lenalidomide for Relapsed DLBCL in Italy

  This study is testing if a combination of two medications, tafasitamab and lenalidomide, can help people in Italy with relapsed diffuse large B-cell lymphoma who can't have a transplant.

  Recruiting Incyte Biosciences Italy S.r.l · Milan · NCT06299553

• Combination therapy with Epcoritamab for relapsed aggressive B-cell lymphoma

  This study is testing if adding Epcoritamab to chemotherapy helps people with relapsed aggressive B-cell lymphoma get better before a stem cell transplant and live longer without the disease coming back.

  Recruiting Phase 2 Australasian Leukaemia and Lymphoma Group · Melbourne, Victoria · NCT06287398

• Preventing heart damage in lymphoma patients receiving chemotherapy

  This study is testing if a drug called dexrazoxane can help prevent heart damage in adults with lymphoma who are receiving chemotherapy.

  Recruiting at 25 sites Phase 3 Stichting Hemato-Oncologie voor Volwassenen Nederland · 's-Hertogenbosch and 24 other locations · NCT06220032

• Combining Azacitidine with R-CHOP for treating TP53-mutated DLBCL

  This study is testing if adding Azacitidine to the standard R-CHOP treatment can help people with untreated Diffuse Large B-cell Lymphoma who have TP53 mutations feel better and live longer.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06158399

• Combining lenalidomide with G-CHOP for treating newly diagnosed DLBCL with FL

  This study is testing if adding lenalidomide to the G-CHOP treatment can help people newly diagnosed with diffuse large B-cell lymphoma and follicular lymphoma feel better and live longer.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06151080

• Observing treatment outcomes in DLBCL patients with different genetic subtypes

  This study looks at how different genetic types of diffuse large B-cell lymphoma (DLBCL) respond to treatments to help improve future care for patients.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06026488

• Optimizing lymphodepletion for better outcomes in CAR T cell therapy for lymphoma

  This study is testing different ways to prepare patients with Diffuse Large B Cell Lymphoma for CAR T cell therapy to see which method works best for improving their treatment outcomes.

  Recruiting Phase 1 University Health Network, Toronto · Toronto, Ontario · NCT05950802

• Training for oncologists to improve communication with lymphoma patients

  This study tests a new training program for oncologists to help them communicate better with patients who have diffuse large B-cell lymphoma about their diagnosis and care options.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York and 1 other locations · NCT05940272

Related topics

Quick answers

How many DLBCL - Diffuse Large B Cell Lymphoma clinical trials are recruiting right now?

27, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 12 countries. The most sites are in China (12 trials), United States (6 trials), Australia (2 trials), Germany (1 trial), Netherlands (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 12, Phase 3: 3, Phase 1: 3, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →